Cytori Therapeutics, Inc. (USA) (NASDAQ:CYTX)

oversold

I recently had to abandon a hold-my-nose green thumb on Cytori as hopeless, but I'm not about to give up on a rebound for the company. The stock is close to multiyear lows with the ADVANCE and ATHENA trials of adipose-derived regenerative cells in acute and chronic myocardial infarction continuing to enroll. They've also been awarded a BARDA contract for development of treatments for thermal burns from radiation injury. Long-term, Cytori's technology and prospects are very questionable but they're a decent bet for a rebound at this share price.

Another Crap Biopharma Stock with a product only approved for use in Europe that is absolutely worthless.

http://www.cnbc.com/id/46300316

Cytori Therapeutics is inmerse in a big moment right now. Their bussines is going to get huge as there is a big market for the stem cells applied to heart recovery after heart atacks and also for the breasts surgery.

stem cells dont work

more and more horse trainers and pro sport players arre looking into stem cell its a rocket about to take off.

This company has exciting technology and is selling near the low end of its range.

Strong patent portfolio and the razor/razor blade business model. I've been long for two years and it's paying off.

Great stem cell research company that has great potential.

Stem cell technologies with great future,GE mixe alread with...

Compared to other stem cell technologies, deriving the stem cells from from liposuction is the least controversial and invasive, with significant benefits still attainable. It is not a panacea, but it has its applicability.

They extract stem cells from the patient, and can build tissue with it. Cutting edge technology.

cytx

cause fools say it won't

This is still a very promising stock for the future, and after being severely punished this week it will certainly start to increase again.

The Regenerative Medicine market is expected to grow to $3 billion by 2015. Cytori Therapeutics (CYTX) is the early leader in this market and is now treating, on a daily basis, more patients than any competing stem cell company. Given the large patent portfolio, existing approval in 42 countries, pending US FDA approval, partnerships with GE and Olympus, and high margin business model we expect Cytori to maintain its leadership position with sales approaching $1 billion over the next 5 years. With a similar growth pattern Intuitive Surgical (ISRG) carried a $10 billion valuation when it was at the same sales level. We expect the leader in the faster growing regenerative medicine market to carry an equal or greater market cap. Expect US FDA approval to be the key catalyst over the next 12 months.

Cytori is bursting with potential. Between their groundbreaking treatments with the celution machine, their pending FDA approval in the U.S., multiple clinical studies, established markets in Europe and Japan, corporate partnerships with GE and Olympus, multiple patents, and visionary managment, Cytori is well positioned to not only participate in new stem cell markets but dominate them. This stock is just getting started, and should have a wild ride up over the next five years.

This one was due a sharp plunge after an unrealistic run-up. Still, I like it longer-term, with its PureGraft product hitting the market, and other products in the pipeline. PureGraft, a consumable that offers the company a high profit margin, should be a cash generator. Keeping my shares and seeing what kind of cash the company can generate.

Why do shaving cream companies allmost give away their razors? Because they get you on the blades! This is what Cytori is all about. Every time they have a procedure you must reorder the consumables, and that is where the money is.
Companies like GE would not partner with them if there was not a significnt profit potential for them.

The big golden ring, besides breast augmentation,etc. is the future for the heart tests. If it is true that these stem cells can grow back heart function then this is one of the most important advances in medical history.